Analyze Diet
Vaccine2003; 21(31); 4593-4596; doi: 10.1016/s0264-410x(03)00504-8

Rabies DNA vaccine in the horse: strategies to improve serological responses.

Abstract: In order for DNA vaccines to become a practical alternative to conventional vaccines their ability to induce antibody responses in large mammals needs to be improved. We used DNA vaccination against rabies in the horse as a model to test the potential of two different strategies to enhance antibody responses in a large mammalian species. The administration of the DNA vaccine in the presence of aluminum phosphate improved both the onset and the intensity of serological responses but was not potent enough to achieve seroconversion in all vaccinated ponies. However, when the DNA vaccine was formulated with the cationic lipid DMRIE-DOPE instead of aluminum phosphate, a very strong impact on both onset and intensity of serological responses was observed. This latter strategy ensured excellent seroconversion in all vaccinated ponies after a primary course of two injections, demonstrating a clear improvement of the homogeneity of the induced responses. These data indicate that rabies DNA vaccination is feasible in horses and further suggests that properly formulated DNA vaccines can generate immune responses in large veterinary species at a level comparable to the responses achieved with conventional vaccines.
Publication Date: 2003-10-25 PubMed ID: 14575772DOI: 10.1016/s0264-410x(03)00504-8Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study was directed towards exploring strategies for improving the response to DNA vaccines in large mammals, specifically horses, by using a rabies vaccine as a model. Two different strategies were assessed, namely supplementing the vaccine with aluminum phosphate or DMRIE-DOPE, where the latter demonstrated effective and uniform seroconversion in all vaccinated ponies.

Improving Vaccination Strategies

  • The primary focus of the research is to enhance the potential of DNA vaccines, a promising alternative to conventional vaccines but currently underperforming in inducing antibody responses, especially in large mammals.
  • The researchers used a rabies DNA vaccine in horses as a model to test and improve the efficacy and response to DNA vaccines.
  • The enhancement strategies deployed involved the addition of certain compounds to the DNA vaccine, tested to determine their potential to amplify and quicken the onset of serological responses.

Effects of Aluminum Phosphate

  • The first compound tested was aluminum phosphate, a commonly used vaccine adjuvant known for improving immune responses.
  • The administration of the DNA vaccine in the presence of aluminum phosphate displayed improved results in terms of the onset and intensity of the serological responses.
  • However, the improvement achieved by using aluminum phosphate was not potent enough to induce seroconversion in all the vaccinated ponies, implying that some did not develop the necessary antibodies to fight off the disease.

Benefits of DMRIE-DOPE

  • The second compound used was DMRIE-DOPE, a type of cationic lipid that has shown superior results when formulating vaccines.
  • Unlike aluminum phosphate, DMRIE-DOPE had a significant impact on both the onset and the intensity of the serological responses.
  • Most importantly, this formulation ensured complete seroconversion in all vaccinated ponies even after just a primary course of two injections, indicating that all ponies developed antibodies against the disease. This demonstrated a significant improvement in the consistency of the induced responses.

Implications of the Study

  • The results of this study indicate that DNA vaccination against rabies in horses is a feasible possibility, signifying a major breakthrough in veterinary medicine.
  • The success of this method suggests that properly formulated DNA vaccines can induce immune responses in large veterinary species at a level comparable with, or possibly superior to, responses achieved with conventional vaccines.
  • This finding could revolutionize the future of vaccines, offering a more efficient and effective alternative to the vaccination methods currently in use.

Cite This Article

APA
Fischer L, Minke J, Dufay N, Baudu P, Audonnet JC. (2003). Rabies DNA vaccine in the horse: strategies to improve serological responses. Vaccine, 21(31), 4593-4596. https://doi.org/10.1016/s0264-410x(03)00504-8

Publication

ISSN: 0264-410X
NlmUniqueID: 8406899
Country: Netherlands
Language: English
Volume: 21
Issue: 31
Pages: 4593-4596

Researcher Affiliations

Fischer, Laurent
  • Merial SAS, Biological Discovery Research, 254 rue Marcel Mérieux, 69007 Lyon, France. laurent.fischer@merial.com
Minke, Jules
    Dufay, Nathalie
      Baudu, Philippe
        Audonnet, Jean Christophe

          MeSH Terms

          • Adjuvants, Immunologic
          • Aluminum Compounds
          • Animals
          • Antibodies, Viral / analysis
          • Antibodies, Viral / biosynthesis
          • Antigens, Viral
          • DNA, Complementary / immunology
          • DNA, Complementary / isolation & purification
          • Dose-Response Relationship, Immunologic
          • Glycoproteins / immunology
          • Horses / immunology
          • Lipids
          • Phosphates
          • Quaternary Ammonium Compounds
          • Rabies Vaccines / immunology
          • Reverse Transcriptase Polymerase Chain Reaction
          • Vaccines, DNA / immunology
          • Viral Envelope Proteins / immunology

          Citations

          This article has been cited 8 times.
          1. Desanti-Consoli H, Bouillon J, Chapuis RJJ. Equids' Core Vaccines Guidelines in North America: Considerations and Prospective. Vaccines (Basel) 2022 Mar 4;10(3).
            doi: 10.3390/vaccines10030398pubmed: 35335029google scholar: lookup
          2. Ullas PT, Madhusudana SN, Desai A, Sagar BK, Jayamurugan G, Rajesh YB, Jayaraman N. Enhancement of immunogenicity and efficacy of a plasmid DNA rabies vaccine by nanoformulation with a fourth-generation amine-terminated poly(ether imine) dendrimer. Int J Nanomedicine 2014;9:627-34.
            doi: 10.2147/IJN.S53415pubmed: 24501540google scholar: lookup
          3. Kaur M, Rai A, Bhatnagar R. Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge. Vaccine 2009 Mar 26;27(15):2128-37.
            doi: 10.1016/j.vaccine.2009.01.128pubmed: 19356616google scholar: lookup
          4. Leão LI, Ho PL, Junqueira-de-Azevedo Ide L. Transcriptomic basis for an antiserum against Micrurus corallinus (coral snake) venom. BMC Genomics 2009 Mar 16;10:112.
            doi: 10.1186/1471-2164-10-112pubmed: 19291316google scholar: lookup
          5. Nadin-Davis SA, Fehlner-Gardiner C. Lyssaviruses: current trends. Adv Virus Res 2008;71:207-50.
            doi: 10.1016/S0065-3527(08)00005-5pubmed: 18585530google scholar: lookup
          6. Zhu D, Williams JN, Rice J, Stevenson FK, Heckels JE, Christodoulides M. A DNA fusion vaccine induces bactericidal antibodies to a peptide epitope from the PorA porin of Neisseria meningitidis. Infect Immun 2008 Jan;76(1):334-8.
            doi: 10.1128/IAI.00943-07pubmed: 17967859google scholar: lookup
          7. Mealey RH, Stone DM, Hines MT, Alperin DC, Littke MH, Leib SR, Leach SE, Hines SA. Experimental Rhodococcus equi and equine infectious anemia virus DNA vaccination in adult and neonatal horses: effect of IL-12, dose, and route. Vaccine 2007 Oct 23;25(43):7582-97.
            doi: 10.1016/j.vaccine.2007.07.055pubmed: 17889970google scholar: lookup
          8. Margalith M, Vilalta A. Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. Genet Vaccines Ther 2006 Feb 15;4:2.
            doi: 10.1186/1479-0556-4-2pubmed: 16480501google scholar: lookup